Related Experiment Video

Updated: Aug 21, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumococcal vaccine development

Jan T Poolman1

  • 1R & D Bacterial Vaccine Programme, GlaxoSmithKline Biologicals, Rue de l'Institut, 89 1330 Rixensart, Belgium. jan.poolman@gskbio.com

Expert Review of Vaccines
|October 16, 2004
PubMed

Insights

Pneumococcal conjugate vaccines significantly reduce bacteremia and pneumonia in children, with herd immunity benefiting adults. Ongoing research aims to improve vaccines for broader protection against pneumococcal diseases.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics
  • Infectious Diseases

Background:

  • Pneumococcal conjugate vaccines (PCVs) have reduced invasive pneumococcal disease in children.
  • Herd immunity from childhood vaccination benefits unvaccinated populations.
  • Existing polysaccharide vaccines target adults but have limitations for nonbacteremic pneumonia.

Purpose of the Study:

  • To review the impact of pneumococcal vaccines on pediatric and adult populations.
  • To highlight the development of higher-valency conjugate vaccines.
  • To discuss the ongoing need for improved adult pneumococcal vaccines.

Main Methods:

  • Review of existing literature and postlicensure data on pneumococcal vaccine efficacy.
  • Analysis of epidemiological trends in pneumococcal disease burden.
  • Examination of current vaccine development pipelines.

Main Results:

  • 7-valent PCV demonstrated significant reductions in pediatric pneumococcal bacteremia and pneumonia.
  • Limited but improving impact on pediatric otitis media.
  • Established efficacy of 23-valent polysaccharide vaccines against adult bacteremia.
  • Persistent high burden of adult nonbacteremic pneumococcal pneumonia.

Conclusions:

  • Pneumococcal conjugate vaccines are highly effective in pediatric populations, conferring indirect benefits to adults.
  • Development of higher-valency PCVs and novel protein-based vaccines is crucial for addressing adult pneumococcal disease burdens.
  • Further research and vaccine innovation are needed to combat pneumococcal pneumonia comprehensively.

More Related Videos

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...